Patents matching “formulation”

US 11173118

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

US 11166957

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Nov 9, 2021 · Expires Nov 4, 2041

US 11166963

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Nov 9, 2021 · Expires Nov 4, 2041

US 11154557

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Oct 26, 2021 · Expires Oct 21, 2041

US 11147841

Enhanced omega-3 formulations

AKER BIOMARINE ANTARCTIC AS · Granted Oct 19, 2021 · Expires Oct 14, 2041

US 11147782

GHB formulation and method for its manufacture

Jazz Pharmaceuticals Ireland Limited · Granted Oct 19, 2021 · Expires Oct 14, 2041

US 11149044

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted Oct 19, 2021 · Expires Oct 14, 2041

US 11141404

Formulations and methods for treating acute cannabinoid overdose

Anebulo Pharmaceuticals, Inc. · Granted Oct 12, 2021 · Expires Oct 7, 2041

US 11141479

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Oct 12, 2021 · Expires Oct 7, 2041

US 11141378

Lipid formulations for nucleic acid delivery

ARBUTUS BIOPHARMA CORPORATION · Granted Oct 12, 2021 · Expires Oct 7, 2041

US 11135267

Etanercept formulations stabilized with metal ions

Coherus BioSciences, Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

US 11129808

PKC-delta-I inhibitor formulations and uses thereof

THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERRANS AFFAIRS OFFICE OF THE GENERAL COUNSEL · Granted Sep 28, 2021 · Expires Sep 23, 2041

US 11129876

Etanercept formulations stabilized with amino acids

Coherus BioSciences, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

US 11129818

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

US 11123286

Auris formulations for treating otic diseases and conditions

The Regents of the University of California · Granted Sep 21, 2021 · Expires Sep 16, 2041

US 11123351

Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

Umecrine Cognition AB · Granted Sep 21, 2021 · Expires Sep 16, 2041

US 11123285

Auris formulations for treating OTIC diseases and conditions

The Regents of the University of California · Granted Sep 21, 2021 · Expires Sep 16, 2041

US 11123302

Formulation of acoustically activatable particles having low vaporization energy and methods for using same

Arizona Board of Regents on Behalf of the University of Arizona · Granted Sep 21, 2021 · Expires Sep 16, 2041

US 11110063

Storage stable sincalide formulations

MAIA PHARMACEUTICALS, INC. · Granted Sep 7, 2021 · Expires Sep 2, 2041

US 11110093

Sustained release small molecule drug formulation

Indivior UK Limited · Granted Sep 7, 2021 · Expires Sep 2, 2041

US 11110099

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Sep 7, 2021 · Expires Sep 2, 2041

US 11103552

High concentration VEGF receptor fusion protein containing formulations

REGENERON PHARMACEUTICALS, INC. · Granted Aug 31, 2021 · Expires Aug 26, 2041

US 11103513

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Aug 31, 2021 · Expires Aug 26, 2041

US 11098127

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Aug 24, 2021 · Expires Aug 19, 2041